Why The Amgen/Regeneron Patent Saga Is Far From Over
January 09, 2017 at 12:27 PM EST
Despite the District Court’s ruling in favor of Amgen, Inc. (NASDAQ: AMGN) over cholesterol drug Praluent, Leerink believes the ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.